1. ALLA AKTIER
  2. NYHETER
  3. 2CUREX

2cureX

Nyheter 2cureX Nyheter alla bolag

Revised Financial Calendar Announcement

2cureX AB has revised its financial calendar to align with its strategic shift and previously announced reductions in operational spending.

As part of this broad adjustment to business activities, and in accordance with Nasdaq guidelines, 2cureX will limit the number of quarterly reports for Q2 and Q4.
Additionally, due to reduced activities and available resources, and to ensure thorough preparation, the Annual General Meeting (AGM) has been rescheduled from June 20th to June 28th, 2024.
The updated financial calendar reflects these changes.

For more information about 2cureX:

Kenneth Graabek Johansen, Acting Chief Executive Officer & Chief Financial Officer
E-mail: kgj@2curex.com
Telephone: +45 23 49 02 27
www.2curex.com

Ole Thastrup, Vice-Chairman
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB

Attachments

Revised Financial Calendar Announcement

Datum 2024-05-27, kl 21:45
Källa MFN
Bifogade filer
Revised Financial Calendar Announcement
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!